Results 121 to 130 of about 152,273 (295)
Cytometry Part A, EarlyView.ABSTRACT Rapid advancements in mass and flow cytometry technologies have allowed researchers to generate and analyze high‐dimensional single cell datasets, often utilizing upwards of 40 protein markers. Such high‐parameter cytometry is increasingly used in longitudinal immunological studies, but technical variations across experimental batch runs can ...
Shruti Eswar +5 more
wiley +1 more source
The diverse N-glycosylation profiles of CD4+CD25- and CD4+CD25+ T cells in Hashimoto’s thyroiditis
Frontiers in ImmunologyHashimoto’s thyroiditis (HT) is one of the most common organ-specific autoimmune diseases, characterized by chronic thyroid gland inflammation. Helper T (Th) CD4+ cells, whose surface receptors are highly glycosylated, are involved in the pathomechanism ...
Sara Trzos +8 more
doaj +1 more source
Mature T‐cell leukemia/lymphoma with an NK‐like immunophenotype: A report of 7 cases
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Distinguishing T‐cell from NK‐cell neoplasms can occasionally be challenging, as neoplastic T cells can lose T‐cell markers such as surface CD3 (sCD3) and CD5 while acquiring NK‐cell markers such as CD16, CD56, and CD94. In this study, we present a series of 7 mature T‐cell lymphoma/leukemia cases with NK‐like immunophenotypes to clarify ...
Wei J. Wang +8 more
wiley +1 more source
BMC CancerBackground Regulatory T (Treg) cells reportedly play crucial roles in tumor angiogenesis as well as antitumor immunity. In order to explore their therapeutic potential, we investigated the precise prognostic impact of Treg markers in endometrial ...
Asami Suto +13 more
doaj +1 more source
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean +2 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Phenotype and Function of CD25-Expressing B Lymphocytes Isolated from Human Umbilical Cord Blood
Clinical and Developmental Immunology, 2011 Background. We have shown that approximately 30% of human peripheral blood B-cells express CD25. B cells expressing CD25 display a mature phenotype belonging to the memory B-cell population and have a better proliferative and antigen-presenting capacity.
Sylvie Amu, Mikael Brisslert
doaj +1 more source
Epilepsia, EarlyView.Abstract Objective This study was undertaken to evaluate whether synaptic vesicle protein 2A (SV2A) expression on peripheral immune cells predicts treatment response to levetiracetam in epilepsy. Methods High‐dimensional flow cytometry was used to prospectively assess SV2A expression on immune cells from levetiracetam responders, nonresponders, and ...
Johannes Lang +4 more
wiley +1 more source
The multiple hit model of infantile and epileptic spasms: The 2025 update
Epilepsia Open, EarlyView.Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou +6 more
wiley +1 more source
International Journal of Cancer, EarlyView.Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim +22 more
wiley +1 more source